Patents Assigned to Afraxis Holdings, Inc.
  • PAK INHIBITORS FOR THE TREATMENT OF FRAGILE X SYNDROME
    Publication number: 20150031693
    Abstract: Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of Fragile X syndrome.
    Type: Application
    Filed: November 2, 2012
    Publication date: January 29, 2015
    Applicant: AFRAXIS HOLDINGS, INC.
    Inventors: John C. Mckew, Wenwei Huang, David Campbell, Sergio G. Durön, Mark Behnke, Min Shen
  • 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
    Patent number: 8912203
    Abstract: Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: December 16, 2014
    Assignee: Afraxis Holdings, Inc.
    Inventors: David Campbell, Sergio G. Duron, Benedikt Vollrath, Warren Wade
  • SERINE/THREONINE KINASE INHIBITORS
    Publication number: 20140323478
    Abstract: Compounds having the formula I, or a pharmaceutically acceptable salt thereof, wherein R1, R2, X1, X2, and Ar are as defined herein, are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.
    Type: Application
    Filed: April 30, 2014
    Publication date: October 30, 2014
    Applicant: AFRAXIS HOLDINGS, INC.
    Inventors: Sergio DURÓN, David CAMPBELL, Chudi NDUBAKU, Joachim RUDOLPH
  • 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER
    Publication number: 20140163026
    Abstract: Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders or neurofibromatosis. Also described herein are methods of utilizing PAK inhibitors for the treatment of cancer.
    Type: Application
    Filed: April 9, 2012
    Publication date: June 12, 2014
    Applicant: Afraxis Holdings, Inc.
    Inventors: David Campbell, Sergio G. Duron
  • 6-(ethynyl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
    Patent number: 8680099
    Abstract: Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: March 25, 2014
    Assignee: Afraxis Holdings, Inc.
    Inventors: David Campbell, Sergio G. Duron, Benedikt Vollrath, Warren Wade
  • Compounds for treating neuropsychiatric conditions
    Patent number: 8674095
    Abstract: Provided herein are pyrido[2,3-D]pyrimidin-7(8H)-one compounds and compositions useful as PAK inhibitors. Also provided herein are methods of utilizing these compounds for the treatment of neuropsychiatric conditions. The compounds modulate dendritic spine morphology and/or synaptic function.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: March 18, 2014
    Assignee: Afraxis Holdings, Inc.
    Inventors: David Campbell, Sergio G. Durón, Benedikt Vollrath, Warren Wade